Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$203.90 USD

203.90
318,140

+2.36 (1.17%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $203.96 +0.06 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.

Here's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks

The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.

Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Steris (STE) Up 5.8% Since Last Earnings Report?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.

Why Steris (STE) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Steris (STE) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up

STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.

Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics

The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Steris (STE) Q3 Earnings and Revenues Top Estimates

Steris (STE) delivered earnings and revenue surprises of 2.30% and 4.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stocks' Earnings Due on Feb 7: STE, PAHC & NVST

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.

Countdown to Steris (STE) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline

Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STERIS (STE) Set to Post Q3 Earnings: What's in the Cards?

STERIS' (STE) third-quarter fiscal 2024 results are likely to reflect solid performance across both the Healthcare and AST segments.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.

Why Is Steris (STE) Down 3.4% Since Last Earnings Report?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.

STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down

STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.

Steris (STE) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Steris (STE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2023.

Orthofix (OFIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Orthofix (OFIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.